1.Subacute Combined Degeneration of the Spinal Cord in Association with Pernicious Anemia: A case report.
Noh Kyoung PARK ; Dong Soo KIM ; Jong Hyun LEE ; Jang Hun YOU ; In Han CHO
Journal of the Korean Academy of Rehabilitation Medicine 2005;29(6):678-680
Subacute combined degeneration is a disease of spinal cord involving the posterior and lateral columns due to vitamin B12 deficiency. We experienced a 56-year-old man suffering subacute combined degeneration, characterised by dysesthesia and disturbance of deep sensation such as position sense, proprioception and vibration sense in the lower extremities, and ataxic gait. We reported one patient with subacute combined degeneration of the cord in association with pernicious anemia resulting from inactivation of intrinsic factor by it's antibodies.
Anemia, Pernicious*
;
Antibodies
;
Gait
;
Humans
;
Intrinsic Factor
;
Lower Extremity
;
Middle Aged
;
Paresthesia
;
Proprioception
;
Sensation
;
Spinal Cord*
;
Subacute Combined Degeneration*
;
Vibration
;
Vitamin B 12 Deficiency
2.Recurrent Stent Thrombosis in a Patient with Antiphospholipid Syndrome and Dual Anti-Platelet Therapy Non-Responsiveness.
You Hong LEE ; Hyoung Mo YANG ; Seung Jea TAHK ; You Sun HONG ; Jin Sun PARK ; Kyoung Woo SEO ; Yong Woo CHOI ; Choong Kyun NOH
Korean Circulation Journal 2015;45(1):71-76
Antiphospholipid syndrome (APS), the most common acquired hypercoagulable condition, is diagnosed by persistent presence of antiphospholipid antibodies and episodes of vascular thrombosis. It may be an important predisposing factor for stent thrombosis, resulting in poor outcomes. Also, anti-platelet therapy non-responsiveness is associated with stent thrombosis. We report a case of a 39-year-old man who after undergoing successful percutaneous coronary intervention for significant coronary artery disease suffered repeated stent thrombosis events leading to ST-segment elevation myocardial infarction. Eventually, he underwent coronary artery bypass surgery because of uncontrolled thrombosis and was diagnosed as having APS and dual antiplatelet therapy non-responsiveness.
Adult
;
Antibodies, Antiphospholipid
;
Antiphospholipid Syndrome*
;
Causality
;
Coronary Artery Bypass
;
Coronary Artery Disease
;
Humans
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Stents*
;
Thrombosis*
3.Sex-Biased Molecular Signature for Overall Survival of Liver Cancer Patients
Sun Young KIM ; Hye Kyung SONG ; Suk Kyeong LEE ; Sang Geon KIM ; Hyun Goo WOO ; Jieun YANG ; Hyun-Jin NOH ; You-Sun KIM ; Aree MOON
Biomolecules & Therapeutics 2020;28(6):491-502
Sex/gender disparity has been shown in the incidence and prognosis of many types of diseases, probably due to differences in genes, physiological conditions such as hormones, and lifestyle between the sexes. The mortality and survival rates of many cancers, especially liver cancer, differ between men and women. Due to the pronounced sex/gender disparity, considering sex/ gender may be necessary for the diagnosis and treatment of liver cancer. By analyzing research articles through a PubMed literature search, the present review identified 12 genes which showed practical relevance to cancer and sex disparities. Among the 12 sex-specific genes, 7 genes (BAP1, CTNNB1, FOXA1, GSTO1, GSTP1, IL6, and SRPK1) showed sex-biased function in liver cancer. Here we summarized previous findings of cancer molecular signature including our own analysis, and showed that sexbiased molecular signature CTNNB1High , IL6High , RHOAHigh and GLIPR1Low may serve as a female-specific index for prediction and evaluation of OS in liver cancer patients. This review suggests a potential implication of sex-biased molecular signature in liver cancer, providing a useful information on diagnosis and prediction of disease progression based on gender.
4.Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study.
Jee Man YOU ; Yun Gyoung KIM ; Hyeong Gon MOON ; Seok Jin NAM ; Jong Won LEE ; Woosung LIM ; Mi Ri LEE ; Dong Young NOH ; Wonshik HAN
Journal of Breast Cancer 2015;18(1):8-15
PURPOSE: The aim of this study was to investigate whether the observed changes over time in the survival rates vary according to the intrinsic subtypes of breast cancer diagnosed. METHODS: Data from 46,320 breast cancer patients in the Korean Breast Cancer Registry who underwent surgery between 1999 and 2006 were reviewed. Among them, results from 25,887 patients with available data about the status of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) were analyzed. Patients were classified into two cohorts according to the year in which they underwent surgery: 1999-2002 and 2003-2006. RESULTS: The patients treated in the latter time period showed significantly better overall survival (OS) compared with those in the former period when adjusted for follow-up duration. The proportion of hormone receptor+/HER2-subtype and stage I breast cancer were significantly higher in the latter period (47.4% vs. 54.6%, p<0.001; 31.0% vs. 39.6%, p<0.001, respectively). Improvement in OS between the former and latter periods was seen in all subtypes of breast cancer, including triple-negative cancers (all p-values <0.001 in univariate and multivariate analyses). CONCLUSION: Improvement in survival in Korean breast cancer patients over the study years is being observed in all subtypes of breast cancer, implying that increases in both early-stage detection and the proportion of less aggressive cancers contribute to this improvement.
Breast Neoplasms*
;
Cohort Studies
;
Estrogens
;
Follow-Up Studies
;
Humans
;
Korea
;
Receptor, Epidermal Growth Factor
;
Receptors, Progesterone
;
Registries
;
Survival Rate
5.Establishment of SNU cell lines: november 1989-august 1990.
Jae Gahb PARK ; You Me JEON ; Kyu Ju PARK ; Han Kwang YANG ; Dong Young NOH ; Sun Whe KIM ; Seung Keun OH ; Kuhn Uk LEE ; Yong Hyun PARK ; Kuk Jin CHOE ; Jin Pok KIM ; Soo Tae KIM
Journal of the Korean Cancer Association 1991;23(2):169-187
No abstract available.
Cell Line*
6.Increased humoral antibody response of foot-and-mouth disease virus vaccine in growing pigs pre-treated with poly-γ-glutamic acid.
Jee Hoon LEE ; Ik Jae KANG ; A Reum KIM ; You Sun NOH ; Hee Chun CHUNG ; Bong Kyun PARK
Journal of Veterinary Science 2016;17(2):253-256
This study was conducted to determine if humoral antibody response of foot-and-mouth disease (FMD) vaccine improved in 8-week-old growing pigs born to well-vaccinated sows pre-treated with 60 mg of poly-γ-glutamic acid (γ-PGA) three days before vaccination. Antibody against FMD virus serotype O was measured 0, 2, 4 and 6 weeks post-vaccination, using a PrioCHECK FMDV type O ELISA kit. The results showed that positive antibody reactions against FMDV serotype O antigen among a component of the vaccine significantly increased in response to pre-injection with γ-PGA.
Animals
;
Antibody Formation*
;
Enzyme-Linked Immunosorbent Assay
;
Foot-and-Mouth Disease Virus*
;
Foot-and-Mouth Disease*
;
Immunity, Humoral
;
O Antigens
;
Serogroup
;
Swine*
;
Vaccination
8.Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis.
Hyun Beom CHAE ; Yoon Suk JUNG ; Dong Il PARK ; Chang Kyun LEE ; Kyu Chan HUH ; Jeong Eun SHIN ; Jae Hak KIM ; You Sun KIM ; Yunho JUNG ; Sung Ae JUNG ; Hyun Ju SONG ; Hyun Joo JANG ; Sung Noh HONG ; Young Ho KIM
The Korean Journal of Gastroenterology 2014;64(2):93-97
BACKGROUND/AIMS: Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis. METHODS: From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis. RESULTS: Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039). CONCLUSIONS: Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.
Adult
;
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Colitis, Ulcerative/*diagnosis/drug therapy/pathology
;
Female
;
Follow-Up Studies
;
Hospitalization
;
Humans
;
Infliximab/therapeutic use
;
Logistic Models
;
Male
;
Mesalamine/therapeutic use
;
Middle Aged
;
Odds Ratio
;
Prognosis
;
Retrospective Studies
;
Time Factors
9.Differences in Clinical Manifestations according to the Positivity of Interferon-γ Assay in Patients with Intestinal Tuberculosis.
Hye Jin JUNG ; Young Ho KIM ; You Sun KIM ; Seong Yeon JEONG ; Sung Won PARK ; Ji Yeon SEO ; Hyemi JUNG ; Jong Pil IM ; Ji Won KIM ; Sung Noh HONG ; Kuk Lae LEE
Gut and Liver 2016;10(4):649-652
Intestinal tuberculosis (ITB) remains prevalent in Asia. An interferon-γ assay (QuantiFERON-TB gold test [QFT]) is considered to be an effective supplementary tool for diagnosing ITB. We retrospectively analyzed the clinical features of ITB patients based on the initial results of QFT. A total of 109 patients with ITB were enrolled, and 82 patients (75.2%) showed positive QFT results. In the QFT-positive group, the mean age (44.1±12.0 years) was significantly higher than that in the QFT-negative group (37.0±14.8, p=0.0096). Abdominal pain (p=0.006) and diarrhea (p=0.030) were more frequent in the QFT-negative group. Further, C-reactive protein (CRP) levels were significantly higher in the QFT-negative group (6.4±9.9 mg/dL) than in the QFT-positive group (1.3±2.3, p<0.001). Multivariate analysis confirmed that younger age (p=0.016), diarrhea (p=0.042), and high levels of CRP (p=0.029) were independent predictors of QFT-negative results in patients with ITB. These results suggest that prior exposure to TB, reflected by QFT positivity, may cause mild inflammation in patients with ITB.
Abdominal Pain
;
Asia
;
C-Reactive Protein
;
Diarrhea
;
Humans
;
Inflammation
;
Multivariate Analysis
;
Retrospective Studies
;
Tuberculosis*
10.Long-term Outcomes after the Discontinuation of Anti-TumorNecrosis Factor-α Therapy in Patients with Inflammatory BowelDisease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Joo Hye SONG ; Eun Ae KANG ; Soo-Kyung PARK ; Sung Noh HONG ; You Sun KIM ; Ki Bae BANG ; Kyeong Ok KIM ; Hong Sub LEE ; Sang-Bum KANG ; Seung Yong SHIN ; Eun Mi SONG ; Jong Pil IM ; Chang Hwan CHOI ;
Gut and Liver 2021;15(5):752-762
Background/Aims:
Our study aimed to evaluate the long-term outcomes and risk factors forrelapse after anti-tumor necrosis factor (TNF)-α cessation in inflammatory bowel disease (IBD) patients because they are not well established.
Methods:
A retrospective multicenter cohort study was conducted involving patients with Crohn’s disease (CD) or ulcerative colitis (UC) from 10 referral hospitals in Korea who discontinued firstline anti-TNF therapy after achieving clinical remission.
Results:
A total of 109 IBD patients (71 CD and 38 UC) with a median follow-up duration of 56months were analyzed. The cumulative relapse rates at 1, 3, and 5 years were 11.3%, 46.7%, and 62.5% for CD patients and 28.9%, 45.3%, and 60.9% for UC patients. Multivariable Coxanalysis revealed that discontinuation owing to the clinician’s decision was associated with lower risk of relapse (vs patient’s preference: hazard ratio [HR], 0.13; 95% confidence interval [CI], 0.04 to 0.48; p=0.002) and adalimumab use was associated with higher risk of relapse (vs infliximab: HR, 4.42; 95% CI, 1.24 to 17.74; p=0.022) in CD patients. Mucosal healing was associated with lower risk of relapse (vs nonmucosal healing: HR, 0.12; 95% CI, 0.02 to 0.83; p=0.031) in UC patients. Anti-TNF re-induction was provided to 52 patients, and a response was obtained in 50 patients. However, 25 of them discontinued retreatment owing to a loss of response (n=15), the patient’s preference (n=6), and other factors (n=4).
Conclusions
More than 60% of IBD patients in remission under anti-TNF therapy relapsed within 5 years of treatment cessation. Anti-TNF re-induction was effective. However, half of the patients discontinued anti-TNF therapy, and 50% of these patients discontinued treatment owing to loss of response.